Presence of cytogenetic abnormalities by vital status and age-adjusted univariate HRs between cytogenetic abnormalities and OS
| . | At risk, n (%) . | Death, n (%) . | Age-adjusted HRs∗ (95% CI) . |
|---|---|---|---|
| 116 (64.1) | 65 (35.9) | ||
| IMWG HRCA classification† | |||
| Standard risk | 100 (86.2) | 50 (79.4) | 1.0 (Referent)‡ |
| High risk | 16 (26.2) | 13 (41.9) | 1.7 (0.9-3.1) |
| t(4;14)(p16;q32) | |||
| No | 93 (95.9) | 43 (86.0) | 1.0 (Referent)‡ |
| Yes | 4 (4.1) | 7 (14.0) | 2.5 (1.1-5.5) |
| t(11;14)(q13;q32) | |||
| No | 16 (72.7) | 14 (82.3) | 1.0 (Referent)‡ |
| Yes | 6 (27.3) | 3 (17.6) | 0.7 (0.2-2.3) |
| t(14;16)(q32;q23) | |||
| No | 42 (97.7) | 18 (90.0) | 1.0 (Referent)‡ |
| Yes | 1 (2.3) | 2 (10.0) | 3.8 (0.8-17.1) |
| t(14;20)(q32;q12) | |||
| No | 36 (97.3) | 16 (100.0) | — |
| Yes | 1 (2.7) | 0 (0.0) | — |
| Loss of IGH | |||
| No | 43 (67.2) | 22 (73.3) | 1.0 (Referent)‡ |
| Yes | 21 (32.8) | 8 (26.7) | 0.7 (0.3-1.7) |
| IGH rearrangement | |||
| No | 58 (76.3) | 23 (63.9) | 1.0 (Referent)‡ |
| Yes | 18 (23.7) | 13 (36.1) | 1.6 (0.8-3.1) |
| Trisomy of chromosome 3 | |||
| No | 59 (73.8) | 22 (78.6) | 1.0 (Referent)‡ |
| Yes | 21 (26.2) | 6 (21.4) | 0.8 (0.3-1.9) |
| Trisomy of chromosome 7 | |||
| No | 47 (79.7) | 15 (71.4) | 1.0 (Referent)‡ |
| Yes | 12 (20.3) | 6 (28.6) | 2.0 (0.8-5.2) |
| Trisomy of chromosome 9 | |||
| No | 52 (61.9) | 19 (61.3) | 1.0 (Referent)‡ |
| Yes | 32 (38.1) | 12 (38.7) | 1.1 (0.5-2.2) |
| Chromosome 13q deletion (del 13q) | |||
| No | 84 (75.7) | 39 (63.9) | 1.0 (Referent)‡ |
| Yes | 27 (24.3) | 22 (36.1) | 1.6 (0.9-2.6) |
| Loss of ATM [11q22.3)] (del 11q) | |||
| No | 97 (98.0) | 52 (100.0) | — |
| Yes | 2 (2.0) | 0 (0.0) | — |
| Gain of ATM | |||
| No | 30 (48.4) | 15 (45.5) | 1.0 (Referent)‡ |
| Yes | 32 (51.6) | 18 (54.5) | 0.9 (0.4-1.9) |
| Loss of TP53 [17p13.1] (del 17p) | |||
| No | 95 (86.4) | 54 (90.0) | 1.0 (Referent)‡ |
| Yes | 15 (13.6) | 6 (10.0) | 0.9 (0.4-2.1) |
| Gain of TP53 | |||
| No | 50 (83.3) | 28 (82.3) | 1.0 (Referent)‡ |
| Yes | 10 (16.7) | 6 (17.6) | 1.2 (0.5-3.0) |
| Loss of CDKN2C [1p32.3] (del 1p) | |||
| No | 74 (93.7) | 27 (100.0) | — |
| Yes | 5 (6.3) | 0 (0.0) | — |
| Gain/amplification of CKS1B [1q21] (gain/amplification of 1q) | |||
| No | 60 (69.0) | 15 (48.4) | 1.0 (Referent)‡ |
| Yes | 27 (31.0) | 16 (51.6) | 2.4 (1.2-4.9) |
| Tetraploidy | |||
| No | 7 (33.3) | 5 (45.5) | 1.0 (Referent)‡ |
| Yes | 14 (66.7) | 6 (54.5) | 0.6 (0.2-2.1) |
| . | At risk, n (%) . | Death, n (%) . | Age-adjusted HRs∗ (95% CI) . |
|---|---|---|---|
| 116 (64.1) | 65 (35.9) | ||
| IMWG HRCA classification† | |||
| Standard risk | 100 (86.2) | 50 (79.4) | 1.0 (Referent)‡ |
| High risk | 16 (26.2) | 13 (41.9) | 1.7 (0.9-3.1) |
| t(4;14)(p16;q32) | |||
| No | 93 (95.9) | 43 (86.0) | 1.0 (Referent)‡ |
| Yes | 4 (4.1) | 7 (14.0) | 2.5 (1.1-5.5) |
| t(11;14)(q13;q32) | |||
| No | 16 (72.7) | 14 (82.3) | 1.0 (Referent)‡ |
| Yes | 6 (27.3) | 3 (17.6) | 0.7 (0.2-2.3) |
| t(14;16)(q32;q23) | |||
| No | 42 (97.7) | 18 (90.0) | 1.0 (Referent)‡ |
| Yes | 1 (2.3) | 2 (10.0) | 3.8 (0.8-17.1) |
| t(14;20)(q32;q12) | |||
| No | 36 (97.3) | 16 (100.0) | — |
| Yes | 1 (2.7) | 0 (0.0) | — |
| Loss of IGH | |||
| No | 43 (67.2) | 22 (73.3) | 1.0 (Referent)‡ |
| Yes | 21 (32.8) | 8 (26.7) | 0.7 (0.3-1.7) |
| IGH rearrangement | |||
| No | 58 (76.3) | 23 (63.9) | 1.0 (Referent)‡ |
| Yes | 18 (23.7) | 13 (36.1) | 1.6 (0.8-3.1) |
| Trisomy of chromosome 3 | |||
| No | 59 (73.8) | 22 (78.6) | 1.0 (Referent)‡ |
| Yes | 21 (26.2) | 6 (21.4) | 0.8 (0.3-1.9) |
| Trisomy of chromosome 7 | |||
| No | 47 (79.7) | 15 (71.4) | 1.0 (Referent)‡ |
| Yes | 12 (20.3) | 6 (28.6) | 2.0 (0.8-5.2) |
| Trisomy of chromosome 9 | |||
| No | 52 (61.9) | 19 (61.3) | 1.0 (Referent)‡ |
| Yes | 32 (38.1) | 12 (38.7) | 1.1 (0.5-2.2) |
| Chromosome 13q deletion (del 13q) | |||
| No | 84 (75.7) | 39 (63.9) | 1.0 (Referent)‡ |
| Yes | 27 (24.3) | 22 (36.1) | 1.6 (0.9-2.6) |
| Loss of ATM [11q22.3)] (del 11q) | |||
| No | 97 (98.0) | 52 (100.0) | — |
| Yes | 2 (2.0) | 0 (0.0) | — |
| Gain of ATM | |||
| No | 30 (48.4) | 15 (45.5) | 1.0 (Referent)‡ |
| Yes | 32 (51.6) | 18 (54.5) | 0.9 (0.4-1.9) |
| Loss of TP53 [17p13.1] (del 17p) | |||
| No | 95 (86.4) | 54 (90.0) | 1.0 (Referent)‡ |
| Yes | 15 (13.6) | 6 (10.0) | 0.9 (0.4-2.1) |
| Gain of TP53 | |||
| No | 50 (83.3) | 28 (82.3) | 1.0 (Referent)‡ |
| Yes | 10 (16.7) | 6 (17.6) | 1.2 (0.5-3.0) |
| Loss of CDKN2C [1p32.3] (del 1p) | |||
| No | 74 (93.7) | 27 (100.0) | — |
| Yes | 5 (6.3) | 0 (0.0) | — |
| Gain/amplification of CKS1B [1q21] (gain/amplification of 1q) | |||
| No | 60 (69.0) | 15 (48.4) | 1.0 (Referent)‡ |
| Yes | 27 (31.0) | 16 (51.6) | 2.4 (1.2-4.9) |
| Tetraploidy | |||
| No | 7 (33.3) | 5 (45.5) | 1.0 (Referent)‡ |
| Yes | 14 (66.7) | 6 (54.5) | 0.6 (0.2-2.1) |
HRs were calculated using the Cox proportional hazards regression models adjusting for age (years).
IMWG molecular classification of MM: High-risk MM was defined by the presence of any HRCAs, including t(4;14), t(14;16), t(14;20), del 17p, and gain/amplification of 1q 19. Standard-risk MM was defined by the absence of HRCAs or the presence of any trisomies of odd-numbered chromosomes or t(11;14).
The referent category, indicated by an HR of 1.0, serves as the baseline for comparison. HRs for other categories are relative to this baseline.